Literature DB >> 18667806

Multipotential neural precursors transplanted into the metachromatic leukodystrophy brain fail to generate oligodendrocytes but contribute to limit brain dysfunction.

M I Givogri1, D Bottai, H L Zhu, S Fasano, G Lamorte, R Brambilla, A Vescovi, L Wrabetz, E Bongarzone.   

Abstract

Neural stem cells appear to be best suited for regenerative therapy in neurological diseases. However, the effects of high levels of potentially toxic substances such as sulfatides--which accumulate in metachromatic leukodystrophy (MLD)--on this regenerative ability are still largely unclear. To start addressing this question, in vitro and in vivo experiments were used to examine the behavior of multipotential neural precursors exposed to abnormally high levels of sulfatides. Following transplantation of dissociated neurospheres into the brain of presymptomatic MLD pups, the majority of donor-derived cells were distributed in a caudal to rostral direction, with higher numbers in the cortex. Most if not all of the donor cells acquired an astroglial phenotype. We found no evidence of oligodendrocyte or neuronal commitment of transplanted cells in long-term-treated MLD mice (e.g. up to 1.5 years of age). This was in line with our in vitro findings of sulfatides blocking oligodendrocyte formation after induction of differentiation in sulfatide-treated epidermal growth factor/fibroblast growth factor responsive neurospheres. Transplanted MLD mice showed an improved arylsulfatase A (ARSA) activity and a significant amelioration of sulfatide metabolism, neurodegeneration and motor-learning/memory deficits. Furthermore, transplanted cells were shown to act as a source of ARSA enzyme that accumulated in endogenous brain cells, indicating the occurrence of enzyme cross-correction between transplanted and host cells. These results provide a first insight into the effect of sulfatides on the stemness properties of neural stem cells and on the effects of the MLD environment on the in vivo expectations of using neural stem cells in cell therapy. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667806     DOI: 10.1159/000150127

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  19 in total

Review 1.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

2.  Persistence of psychosine in brain lipid rafts is a limiting factor in the therapeutic recovery of a mouse model for Krabbe disease.

Authors:  A B White; F Galbiati; M I Givogri; A Lopez Rosas; X Qiu; R van Breemen; E R Bongarzone
Journal:  J Neurosci Res       Date:  2010-12-29       Impact factor: 4.164

Review 3.  The myelin mutants as models to study myelin repair in the leukodystrophies.

Authors:  Ian D Duncan; Yoichi Kondo; Su-Chun Zhang
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

4.  Dysfunction of platelet-derived growth factor receptor α (PDGFRα) represses the production of oligodendrocytes from arylsulfatase A-deficient multipotential neural precursor cells.

Authors:  Katarzyna C Pituch; Ana L Moyano; Aurora Lopez-Rosas; Felecia M Marottoli; Guannan Li; Chenqi Hu; Richard van Breemen; Jan E Månsson; Maria I Givogri
Journal:  J Biol Chem       Date:  2015-01-20       Impact factor: 5.157

5.  Isolation and Culture of Neural Stem/Progenitor Cells from the Postnatal Periventricular Region.

Authors:  Alessandra Ricca; Federica Cascino; Angela Gritti
Journal:  Methods Mol Biol       Date:  2022

6.  Neural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy.

Authors:  Margherita Neri; Alessandra Ricca; Ilaria di Girolamo; Beatriz Alcala'-Franco; Chiara Cavazzin; Aldo Orlacchio; Sabata Martino; Luigi Naldini; Angela Gritti
Journal:  Stem Cells       Date:  2011-10       Impact factor: 6.277

Review 7.  Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.

Authors:  Paola Sacerdote; Silvia Franchi; Sarah Moretti; Mara Castelli; Patrizia Procacci; Valerio Magnaghi; Alberto E Panerai
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-16       Impact factor: 4.147

8.  Long-term survival of human neural stem cells in the ischemic rat brain upon transient immunosuppression.

Authors:  Laura Rota Nodari; Daniela Ferrari; Fabrizio Giani; Mario Bossi; Virginia Rodriguez-Menendez; Giovanni Tredici; Domenico Delia; Angelo Luigi Vescovi; Lidia De Filippis
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

Review 9.  Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.

Authors:  Faez Siddiqi; John H Wolfe
Journal:  Hum Gene Ther       Date:  2016-07-13       Impact factor: 5.695

10.  Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.

Authors:  Sevil Köse; Fatima Aerts-Kaya; Duygu Uçkan Çetinkaya; Petek Korkusuz
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.